CASE 4-31673A



FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1614

RECEIVED

AULT ET AL.

NOV 1 3 2002

APPLICATION NO: 10/006,311

TECH CENTER 1600/2900

FILED: DECEMBER 4, 2001

FOR: PHARMACEUTICAL COMPOSITIONS FOR THE ORAL DELIVERY

OF PHARMACOLOGICALLY ACTIVE AGENTS

Assistant Commissioner for Patents Washington, D.C. 20231

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

Applicants believe this paper is being filed before the mailing date of a first Office action on the merits and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached PTO-1449 form.

These references were cited in the International Search Report in a corresponding international application. Copies of these references and the search report are enclosed herewith. The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form.

Respectfully submitted,

Novartis Corporation Patent and Trademark Dept. 564 Morris Avenue Summit, NJ 07901-1027 (908) 522-6932

CAL:AK

Encl.: 6 References and a PTO 1449 form

International Search Report

Date: November 7, 2002

Reg. No. 35,590

Attorney for Applicants